Gain of chromosome 18q and translocation t(14;18) are] frequently found in B-cell non-Hodgkin's lymphomas (B-NHL). Increased BCL2 transcription and BCL2 protein expression have been suggested to be the result of the gain. We utilized FISH, PCR and array CGH to study BCL2 and chromosome 18 copy number changes and rearrangements in 93 cases of B-NHL. BCL2 protein was expressed in 475% of the tumor cells in 92% of the cases by immunohistochemistry. Gain of BCL2 was associated with a 25% increase in BCL2 expression levels (immunoblotting), whereas t(14;18) resulted in a 55% increase in BCL2 levels compared to cases without BCL2 alterations. The tumor cell (spontaneous) apoptotic fractions were similar for the cases with different BCL2 genotypes. However, the normal cell apoptotic fractions were higher for the tumors with t(14;18) compared to the tumors without BCL2 alterations, while the tumors with gain of BCL2 only showed intermediate levels.
Introduction
Translocation of the BCL2 gene (18q21.3) to the IGH transcriptional enhancer, as a result of the t(14;18)(q32;q21), causes constitutive overexpression of the antiapoptotic BCL2 protein. 1 Translocation t(14;18) is the primary tumorigenic event in most follicular lymphomas (FL) and some diffuse large B-cell lymphomas (DLBCL). [2] [3] [4] Increased BCL2 levels confer extended survival to B-cells, and may thus cause accumulation of cells likely to be targets for additional oncogenic events and transformation. 5, 6 Gain of chromosome 18 material has been detected frequently in non-Hodgkin's lymphomas (NHL), lymphomas with t(14;18) included. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] It has been suggested that BCL2 could be the target gene in the DLBCL cases with gain of 18q. 19, 20 BCL2 protein expression was enhanced in the tumors with either t (14;18) or BCL2 amplification; the latter two aberrations appeared to be exclusive. 19 This is in agreement with the study of Horsman et al, 17 showing that der(18)t(14;18), not containing the BCL2 coding sequences, was frequently gained in FL cases with BCL2 rearrangement. In contrast, the BCL2 gene was found to be included in the 18q amplica in lymphomas with t(14;18). 21 The proto-oncogene MALT1, also involved in the t(11;18)(q21;q21) translocation, 22 is another possible target in some B-cell non-Hodgkin's lymphomas (B-NHL) with 18q21 gain. 20 The expression of PMAIP1 at locus 18q21.3 was upregulated in transformed FL with 18q21 gain, 21 as well as in some cases of DLBCL. 23 We have studied the impact of BCL2 genotypes on phenotypes such as BCL2 expression, apoptosis, proliferation and survival in 93 cases of B-NHL. Copy number alterations on chromosome 18 were also assessed by array CGH and FISH.
Patients and methods

Tumor samples
Cell suspensions in DMSO prepared from 93 individual lymph node biopsies, histologically and immunologically typed as B-NHL, were included in this study. Preparation of the cellsuspensions, as well as the clinical characteristics and treatment of the patients, has been described in previous studies. 15, 24, 25 Table 1 gives the classification of lymphomas according to WHO, as well as previously published data for gains and losses of chromosome 18 by conventional CGH, DNA index and malignant/normal cell apoptotic fractions. 15, 24 Detection of t(14;18) by conventional and long-range PCR The oligonucleotide primer for the 150-bp MBR was 5 0 -AAC TCT GTG GCA TTA TTG-3 0 and for the mcr 5 0 -GAC TCC TTT ACG TGC TGG TAC-3 0 . The primers were combined with a consensus IGH joining region primer: 5 0 -ACC TGA GGA GAC GGT GAC C-3 0 in the conventional PCR experiments. Longrange PCR, as described by Akasaka et al, 26 was applied to detect translocations outside the MBR and mcr as well. A primer hybridizing to a sequence 5 0 of the MBR (5 0 -CAC AAG TGA AGT CAA CAT GCC TGC CCC AAA CAA AT-3 0 ) was used together with a primer specific for the Em region in the IGH gene (5 0 -CTA GGC CAG TCC TGC TGA CGC CGC ATC GGT GAT TC-3 0 ) for the detection of translocations with breakpoints in the MBR and 3 0 -MBR. 5 0 -mcr and mcr translocations were detected with a primer recognizing a sequence approximately 9.5 kbp 5 0 of the mcr (5 0 -GGT AGA GGT GAA TAC CCC AGG GCT GAG CAG GAA GG-3 0 ) and the Em-primer as above. Cases with MBR or mcr translocations only detectable by long-range PCR, and not by conventional PCR, were assumed to have breakpoints in the 3 0 -MBR or 5 0 -mcr, respectively. As a control for DNA integrity, a 10 560 bp germline sequence 5 0 of the mcr was amplified employing the primers 5 0 -GCG GCT ATT GAG CAC TGA AAT GTG ACT GAA ATG AC-3 0 and 5 0 -CAT CCA ACT GGC TTA GGA GGC AAG ACA GAA ACC TT-3 0 . 0 of the BCL2 coding sequences (assuming no other complicated rearrangements). The number of fusion signals was assumed to represent the total number of derivative chromosomes, while the number of blue centromere 18 signals was used to assess the total number of chromosome 18 and der(18)t (14;18) . If there are no local amplica including the BCL2 gene, an assumption that will be discussed in 'Results and discussion', the number of BCL2 coding sequence copies in the cases with t(14;18) can be calculated as follows: #BCL2 The data for apoptosis were published previously.
d
The BCL2 copy number was derived as described in 'Patients and methods'.
coding sequences ¼ 2 Â #red signals À#red/green fusion signals À#cen 18 signals.
FISH was also applied to examine the copy numbers of sequences corresponding to the RP11-108P20 (MALT1), RP11-103A19 (PMAIP1), RP11-46D1, RP11-563B11 and RP11-154H12 clones on chromosome 18, as well as the RP11-12F16 clone covering PAC820M16 at the telomere of chromosome 14 (BACPAC Resources, Oakland, CA, USA). The DNA was isolated, nick translated and labelled with Cy3-dUTP (Amersham Biosciences, Buckinghamshire, UK). 29 Hybridization was performed with 40 ng of labelled probe and 1 mg Cot-1 DNA (Invitrogen, Carlsbad, CA, USA) in 10 ml 50% formamide, 2 Â SSC, 10% dextran sulfate.
Chromosome 18 copy number alterations examined by array CGH
The genomic microarrays printed covered the human genome at B1 mbp resolution, and contained 77 BAC (RPCI-11 library 30 ) and one PAC clone for chromosome 18 (Wellcome Trust Sanger Institute, Cambridge, UK). The localization of each clone was obtained from Ensembl. DNA isolation, amplification by DOP-PCR and preparation of microarrays were carried out as described previously. 31 The PCR products were arrayed in quadruplicate onto amine-binding slides (CodeLink, Amersham Biosciences). Two sets of duplicate spots were printed in separate areas of the array.
Sequence-verified human cDNA clones (approximately 40 000 clones) were purchased from Invitrogen. The cDNAs were amplified by PCR, purified, resuspended in 3 Â SSC and printed onto two Corning Gamma Amino Propyl Silane (GAPS) slides (Corning, NY, NY, USA) with each of the two slides consisting of 20 000 cDNA clones. The chromosomal position of the printed cDNAs was determined by BLAT analysis of the UCSC human genome browser (http://genome.ucsc.edu/). DNA (1.5 mg) was digested, purified and labelled with Cy3-dCTP or Cy5-dCTP (Perkin Elmer, Boston, MA, USA) as described previously. 31 Labelled tumor and sex-matched reference DNA were combined and ethanol precipitated together with 135 mg human Cot-1 DNA. The DNA and 400 mg yeast tRNA (Invitrogen) was dissolved in 108 ml 50% formamide, 10% dextran sulfate, 4% SDS, 2 Â SSC and denatured for 10 min at 701C. Hybridization (48 h at 371C) and washing was performed in an automated hybridization station, GeneTAC (Genomic Solutions/Perkin-Elmer).
Microarrays were scanned using an Agilent G2565BA scanner (Agilent Technologies, Palo Alto, CA, USA). The spots were segmented, local background was subtracted, and the fluorescence intensities and the intensity ratio of the two dyes were calculated for each spot. Further data processing, including filtering and normalization, was carried out using M-CGH, a MATLAB toolbox specifically designed for this purpose. 
BCL2 protein analysis by immunohistochemistry (IHC) and immunoblotting (IB)
The protocols for IHC and IB, and the interpretation and evaluation of the data, have been described in detail. 25, 28, 33, 34 The anti-BCL2 antiserum C-15 (Santa Cruz Biotech, Santa Cruz, CA, USA) and a monoclonal anti-BCL2 antibody kindly provided by DY Mason (Oxford, UK) were used for IHC and IB, respectively.
Results and discussion
BCL2 genotype
PCR and long-range PCR were used to detect and characterize the translocation t(14;18) involving the BCL2 and IGH loci ( Figure 1a , Table 1 ). t(14;18) was found by PCR in 32 of 36 FL and in five of 18 DLBCL ( Table 1 ). The BCL2 breakpoints were within the MBR in 22 cases (59%) and within the mcr in six (16%) cases, that is, t(14;18) was also detected by standard PCR in these cases (standard PCR data not shown). The breakpoints in the remaining nine cases were distributed between these regions (3 0 -MBR, 5 0 -mcr) ( Table 1 ). The t(14;18) translocations were also assessed by FISH (Figure 1b , Table 1 Table 1) . The latter cases with no relative gain of BCL2 compared to the DNA index were not included in the group with gain of BCL2. The suggested composition and number of chromosome 18 derived chromosomes will be discussed in more detail after presentation of the array CGH results ( Figure 4 , Table 2 ).
BCL2 protein levels and dependence on BCL2 genotype
IHC showed that more than 75% of the tumor cells expressed BCL2 in 79 of 86 tumors examined (Table 1) . Hence, BCL2 expression is a property of the tumor cells in almost all B-NHL. IB could be used to assess the expression levels of BCL2 (Figure 2a , Table 1 ), because of the high fraction of tumor cells in the samples (mean: 75%). 15 The cases with both t(14;18) and BCL2 gain had higher expression of BCL2 (mean: 1.63 relative to p83) than the tumors with t(14;18) only (mean: 1.19; P ¼ 0.008). The latter cases had higher BCL2 levels than the ones with BCL2 gain only (mean: 0.96; P ¼ 0.05), which again had higher BCL2 levels than the tumors with no BCL2 alterations (mean: 0.77; P ¼ 0.03; Figure 2b ). Case 390/87 with loss of one BCL2 allele was excluded from this analysis. Hence, gain of BCL2, in most cases one extra copy, was associated with a 25% increase in BCL2 expression compared to the cases without BCL2 alterations, whereas t(14;18) caused a 55% increase in BCL2 expression. There was no difference in the expression of BCL2 for the different translocation regions (P ¼ 0.70). The expression levels of BCL2 were also compared in 17 cases of DLBCL. Case 34/90 had both t(14;18) and gain of BCL2, four cases showed t(14;18) only, five cases carried BCL2 gain and seven cases had no BCL2 alteration. The mean BCL2 protein levels in these groups of DLBCL cases were 2.22, 1.30, 0.97 and 0.56, respectively, which was similar to the trend observed for the whole material. Hence, the gene dosage effect on BCL2 expression was less pronounced compared to the effect of t(14;18) in this study than in a previous one, 19 where similar BCL2 protein levels were measured in DLBCL with BCL2 amplification and t (14, 18) , respectively.
Cellular and clinical phenotypes and dependence on BCL2 genotype and phenotype
There was a highly significant negative correlation between the expression of BCL2 and levels of spontaneous apoptosis in the tumor cells (Po0.001) (Figure 3a) . The correlation was not very strong (r 2 ¼ 0.11), probably reflecting the fact that mediators other than BCL2 can regulate apoptosis in transformed B cells. [35] [36] [37] However, the median tumor apoptotic fractions in the cases with both t(14;18) and BCL2 gain (0.9%), t(14;18) (1.1%), BCL2 gain (0.9%) and no BCL2 alterations (1.2%) were not different (P ¼ 0.86; Figure 3b) . Surprisingly, levels of spontaneous apoptosis in the normal cells in the t(14;18)-positive tumors without (2.1%) and with (2.3%) BCL2 gain were higher than the corresponding tumor cell apoptotic fractions (P ¼ 0.002 for the cases with t(14;18); Figure 3b (N ¼ 36), with BCL2 gain only (N ¼ 11) and without BCL2 alterations (N ¼ 43), respectively, as assessed by immunofluorescence. Since the average tumor cell fraction was 75%, 15 this means that the large majority of normal cells in the samples were T-lymphocytes. It may be speculated that disruption of an apoptotic pathway (increased BCL2 levels) in the tumor cells may cause the release of proapoptotic mediators causing cell death in normal T-lymphocytes in the affected lymph node.
The median tumor cell S-phase fraction was higher in the B-NHL with BCL2 gain only (6.2%), compared to the cases with t(14;18) (1.1%; Po0.001), and without BCL2 alterations (1.3%; P ¼ 0.02). The normal cell S-phase fractions were not different in the lymphomas with various BCL2 genotypes (0.9-1.5%; P40.17).
Patients with lymphomas with gain of BCL2 only had a poor prognosis (relative risk: 2.9, P ¼ 0.002), in agreement with the results of Bea et al. 38 Cox multivariate survival analysis was employed to assess the prognostic value of BCL2 gain when entered together with the prognostic parameters found in an earlier study (TP53 aberrations, 11q21-23.1 deletions, 6p gain, IPI). 15 The results showed that BCL2 gain only had no independent prognostic value (P ¼ 0.09), probably due to covariation with the (stronger) prognostic parameters 6p gain (P ¼ 0.007), and TP53 aberrations (P ¼ 0.05). The six patients with lymphomas with concomitant BCL2 rearrangement and amplification, as well as the others with t(14;18) only, survived slightly longer than the remaining patients, but the differences were not significant (P40.29).
Our previous study showed that spontaneous apoptosis in the tumor cells has no prognostic value in this tumor material. 39 The apoptotic fraction of the normal cells did not have any prognostic value for the whole group of patients (P ¼ 0.91, cutoff at median ¼ 1.9%), or for the patients with FL (P ¼ 0.62). The gene expression patterns in the normal cells in FL have prognostic value, 40 however, the majority of the genes with prognostic value in this study were not apoptosis associated.
Assessment of DNA copy number changes on chromosome 18 by array CGH and FISH
Array CGH was applied to define amplified regions on chromosome 18 in more detail ( Figure 4 , Table 2, web Table: radium.no/stokke/FTP/Stokke/Chromosome18arrayCGH.xls). The observed ratios in microarray experiments will generally depend on the linearity and dynamic range of the assay, as well as on the fraction of normal cells in the sample, tumor heterogeneity and the DNA index of the tumor. We used the near-diploid DLBCL cell line U698 to test the dynamics of our array CGH platforms. U698 has a narrow amplicon (B1 mbp) at chromosome 6p, which was observed by both BAC and cDNA array CGH. The expected ratio of approximately 10 was observed with one probe on the BAC array (20 copies of the 6p locus by FISH), whereas the ratio at this locus was only two when U698 cells were examined by cDNA array CGH with several more densely spaced probes. Thus, there was not a oneto-one relationship between copy number and ratio in the cDNA array experiments. There was also noise in the data, and the sensitivity for detection of copy number aberrations was much lower for cDNA arrays compared to BAC arrays. The primary tumors also contained an average of 25% normal cells, 15 which tended to bring the ratios towards unity. Hence, the ratios in the BAC array CGH experiments were expected to be somewhat lower than predicted from the copy numbers in the case of gains. No sharp high-level amplifications were detected by BAC array CGH in any of the 93 tumors, and the log 2 ratios varied between À1.05 and þ 0.92 (web Table: radium.no/stokke/FTP/Stokke/Chromosome18arrayCGH.xls). The spacing between the probes on the BAC array was approximately 1 mbp. We therefore employed cDNA arrays with a much closer spacing of the probes (B100 kbp) to reveal any high-level amplification of small regions that could have been missed with the BAC arrays. No gains were detected on chromosome 18 by cDNA array CGH in any of the tumors listed in Table 2 , indicating that there were no high-level amplification of regions of size larger than B100 kbp. FISH showed that one to two extra copies of MALT1 and PMAIP1 were gained compared to the average copy number of the tumors in Table 2 , in agreement with the low-level gains observed by BAC array CGH.
Seven of the tumors with t(14;18) had gains that extended from 18pter to clone ba215a20 at 18q21.33, thus defining the consensus region of gain (defined by at least three tumors). Case 287/88 had gain from the centromere to clone ba215a20. Clone ba215a20 is the closest clone (in this study) centromeric of BCL2, and since the segment recognized by the 14qter probe pac820m16 was gained in seven of these eight tumors ( Figure 4 , Table 2 ; none of these tumors had any other gains on chromosome 14), it is strongly suggested that one extra copy of der (18) 17 which showed that der(18)t(14;18) was frequently gained in FL cases with BCL2 rearrangement. The six other cases with chromosome 18 gain and BCL2 rearrangement showed gain of the entire chromosome 18. There were no indications of local amplica in the tumors with t(14;18), also justifying the calculation of BCL2 copy numbers performed in Table 1 .
Six of the 12 tumors with BCL2 gain, but without translocation had gains extending from 18pter to 18qter, suggesting that an extra copy of the whole chromosome 18 was gained in these cases. Case 390/87, with loss of BCL2, had a narrow amplicon extending from the centromere to ba17i14. The other lymphomas with 18q gain only defined the consensus region to be 18q21.2 (ba116k4)-18qter ( Figure 4) . In case 50/93, the ratio was increased for clone ba28f1, which was in agreement with the five copies detected by FISH for this tumor. However, there was a clear decrease in ratio telomeric of ba28f1 also in cases 154/88, 383/91 and 525/89 (Figure 4) . Also, the ratios appeared to be lower between ba350k6 and ba28f1 in cases 154/88, 383/ 91, 525/89 and 50/93. If these fine structures in the amplica were taken into consideration, the consensus regions of gain were 18q21.2 (ba116k4)-18q21.32 (ba350k6) and 18q21.33 (ba28f1).
Although the level of amplification was lower in the present study employing primary tumor samples, we found the same regions of gain as Sanchez-Izquierdo et al, 20 centered on the BCL2 and MALT1/PMAIP1 loci. However, while the cell lines of MCL and DLBCL origin showed preferential amplification of the region containing the BCL2 locus, 20 we found coamplification of these regions in the primary MCL cases 154/88 and 383/91, and the DLBCL cases 525/89 and 50/93. The high-level gains may be more frequent in B-cell lymphoma lines than in primary tumors, 20 in agreement with the results presented here and in another study. 19 Interestingly, the majority of tumors with BCL2 alterations (Figure 4) , as well as the ones without (radium.no/stokke/FTP/ Stokke/Chromosome18arrayCGH.xls), showed selective loss of the IGH probe ba417p24, covering the region between the D-segments and Ca3. This loss was probably the result of V(D)J, and, in some cases, class switch rearrangements.
Conclusions
In this study, we have shown that whole or partial gains of chromosome 18 are common in B-NHL, both with and without t(14;18). There appears to be a BCL2-collaborating gene in the region 18pter-q21.33 (excluding BCL2), as this was the consensus region of gain for the cases with t(14;18). The low level gain of BCL2 in primary tumors led to elevated BCL2 levels in the t(14;18)-negative cases. Increased BCL2 expression was associated with increased apoptosis in the normal cells in the tumors. The region 18q21.2-18q21.32 was amplified together with the region containing BCL2 in the t(14;18)-negative tumors, indicating that the increased expression of another gene in this region, together with the increased BCL2 expression, is of importance in lymphoma development.
